"ASA in depression"

Investigation the effect of adding ASA to SSRI regimen in patients with major depression disorder (MDD) referring to the clinic Baharan Hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181007041268N1

Enrollment

100

Registered

2019-01-07

Start date

2018-12-22

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Mood [affective] disorders

Interventions

Intervention 1: "Intervention group:" Sertraline receiving a dose of 100 mg and aspirin 80 mg twice daily for 8 weeks. Intervention 2: Control group: The group receiving sertraline at a dose of 100 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Having a definitive diagnosis of moderate and severe depression without receiving treatment until now or since the last stage of the drug is at least 6 months past Not having depression with psychotic features Failure to commit suicide or serious suicidal thoughts People over 18 years old Non-pregnancy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Depression Score in the Beck Questionnaire. Timepoint: Depression score in the Beck questionnaire at the beginning of the study (before the intervention) and at the end of weeks 4 and 8 of the study. Method of measurement: Beck Depression Inventory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Lotfzarei

Zahedan University of Medical Sciences

navidlotfzarei@gmail.com+98 54 3351 3778

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026